Portal de Periódicos da CAPES

High‐dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre

2004; Wiley; Volume: 11; Issue: 7 Linguagem: Inglês

10.1111/j.1468-1331.2004.00813.x

1468-1331

Carsten Boehnke, Uwe Reuter, U. Flach, Sigrid Schuh‐Hofer, K. Einhäupl, G. Arnold,

Ophthalmology and Eye Disorders

The aim of this study was to investigate the efficacy of riboflavin for the prevention of migraine. An open label study was performed in a specialized outpatient clinic. Patients received 400 mg riboflavin capsules per day. Headache frequency, duration, intensity and the use of abortive drugs were recorded at baseline and 3 and 6 months after treatment. Headache frequency was significantly reduced from 4 days/month at baseline to 2 days/month after 3 and 6 months ( P < 0.05). The use of abortive drugs decreased from 7 units/month to 4.5 units/month after 3 and 6 months of treatment ( P < 0.05). In contrast, headache hours and headache intensity did not change significantly. We could demonstrate a significant reduction of headache frequency following riboflavin treatment. In addition, the number of abortive anti‐migraine tablets was reduced. In line with previous studies our findings show that riboflavin is a safe and well‐tolerated alternative in migraine prophylaxis.